Mark Rubinstein to Recombinant Fusion Proteins
This is a "connection" page, showing publications Mark Rubinstein has written about Recombinant Fusion Proteins.
Connection Strength
0.521
-
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.
Score: 0.178
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.136
-
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. J Biol Chem. 2016 Nov 11; 291(46):23869-23881.
Score: 0.122
-
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9166-71.
Score: 0.060
-
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15; 73(10):3075-86.
Score: 0.024